PHIO PHARMACEUTICALS CORP. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
PHIO PHARMACEUTICALS CORP. (PHIO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$103.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$15.00K.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$186.00K, a 112.40% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $98.00K, a 95.10% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$103.00K, a 101.93% decline from fiscal 2016.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $5.35M.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$5.56M, a 290.50% decline from fiscal 2014.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $2.92M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-26 | -$15.00K derived: sum of 2 quarters · filed 2018-03-26 | -$201.00K derived: sum of 3 quarters · filed 2018-03-26 | -$103.00K 10-K · filed 2018-03-26 |
| 2017-09-30 | -$15.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-03-26 | -$201.00K derived: sum of 2 quarters · filed 2018-03-26 | -$103.00K 10-Q/A · filed 2018-03-26 | $1.75M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | -$186.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2018-03-26 | -$88.00K 10-Q/A · filed 2018-03-26 | $1.76M derived: sum of 3 quarters · filed 2018-05-10 | $1.76M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $98.00K 10-Q · filed 2018-05-10 | $1.95M derived: sum of 2 quarters · filed 2018-05-10 | $1.94M derived: sum of 3 quarters · filed 2018-05-10 | $3.44M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $1.85M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-26 | $1.85M derived: sum of 2 quarters · filed 2018-03-26 | $3.35M derived: sum of 3 quarters · filed 2018-03-26 | $5.35M 10-K · filed 2018-03-26 |
| 2016-09-30 | -$2.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-03-26 | $1.50M derived: sum of 2 quarters · filed 2018-03-26 | $3.50M 10-Q/A · filed 2018-03-26 | $5.98M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-06-30 | $1.50M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-03-26 | $3.50M 10-Q/A · filed 2018-03-26 | $5.98M derived: sum of 3 quarters · filed 2018-03-26 | $5.98M derived: sum of 4 quarters · filed 2018-03-26 |
| 2016-03-31 | $2.00M 10-Q/A · filed 2018-03-26 | $4.48M derived: sum of 2 quarters · filed 2018-03-26 | $4.48M derived: sum of 3 quarters · filed 2018-03-26 | -$3.55M derived: sum of 4 quarters · filed 2018-03-26 |
| 2015-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $2.48M derived: sum of 2 quarters · filed 2017-03-30 | -$5.55M derived: sum of 3 quarters · filed 2017-03-30 | -$5.56M 10-K · filed 2017-03-30 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$8.03M derived: sum of 2 quarters · filed 2016-11-10 | -$8.04M 10-Q · filed 2016-11-10 | -$3.05M derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | -$8.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$8.04M 10-Q · filed 2016-08-11 | -$3.05M derived: sum of 3 quarters · filed 2016-08-11 | -$8.06M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | -$8.00K 10-Q · filed 2016-05-12 | $4.98M derived: sum of 2 quarters · filed 2016-05-12 | -$32.00K derived: sum of 3 quarters · filed 2016-05-12 | |
| 2014-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$24.00K derived: sum of 2 quarters · filed 2016-03-30 | $2.92M 10-K · filed 2016-03-30 | |
| 2014-09-30 | -$5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$2.07M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $2.94M 10-Q · filed 2015-08-12 | |||
| 2013-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $5.91M derived: sum of 2 quarters · filed 2015-03-30 | -$3.09M 10-K · filed 2015-03-30 | |
| 2013-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$9.01M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$9.00M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |